We report that parthenolide inhibits tumour progression in PTEN-mutant glioblastoma cells in vitro and in vivo, and suggest that parthenolide has a therapeutic potential as an antitumour agent for glioblastoma. This evidence concerns the gene PTEN and neoplasm.